Semaglutide Improves eGFR Slope vs. Placebo Regardless of Baseline HbA1c and Blood Pressure in People With Type 2 Diabetes: A Post Hoc Analysis of SUSTAIN 6 and PIONEER 6

被引：0
|
作者：
Cherney, David [1 ]
Bosch-Traberg, Heidrun [2 ]
Hadjadj, Samy [3 ]
Kuhlman, Anja B. [2 ]
Rasmussen, Soren [2 ]
Tuttle, Katherine R. [5 ,6 ]
Heerspink, Hiddo J. L. [4 ]
机构：
[1] Univ Hlth Network, Toronto, ON, Canada
[2] Novo Nordisk, Soborg, Denmark
[3] Inst Thorax, Nantes, France
[4] Univ Med Ctr Groningen, Groningen, Netherlands
[5] Univ Washington, Spokane, WA USA
[6] Providence Washington, Spokane, WA USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2022年 / 33卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
SA-PO265
引用
收藏
页码：675 / 675
页数：1
相关论文
共 50 条
  • [41] Cumulative HbA1c exposure as a CVD risk in patients with type 2 diabetes: A post hoc analysis of ACCORD trial
    Cheng, Yi
    Zou, Jun
    Chu, Rui
    Wang, Dan
    Tian, Jingyan
    Sheng, Chang-Sheng
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 206
  • [42] Durable improvement in HbA1c in youth-onset type 2 diabetes with and without background insulin therapy: a post hoc analysis of the DINAMO trial of empagliflozin and linagliptin vs placebo
    Willi, S.
    Laffel, L. M.
    Danne, T.
    Tamborlane, W. V.
    Klingensmith, G. J.
    Neubacher, D.
    Tartakovsky, I.
    Marquard, J.
    Zeitler, P.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S242 - S242
  • [43] Semaglutide improves health-related quality of life vs placebo when added to standard-of care in patients with type 2 diabetes at high risk (SUSTAIN 6)
    Jodar, E.
    Polonsky, W.
    Rea, R.
    Warren, M.
    Vilsboll, T.
    Hakan-Bloch, J.
    Vrazic, H.
    Lindberg, S.
    Bain, S. C.
    DIABETOLOGIA, 2018, 61 : S372 - S373
  • [44] Aquatic training improves HbA1c, blood pressure and functional outcomes of patients with type 2 diabetes: A systematic review with meta-analysis
    Leonel, Larissa dos Santos
    de Brum, Guilherme
    Alberton, Cristine Lima
    Delevatti, Rodrigo Sudatti
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 197
  • [45] Tirzepatide vs. Semaglutide for Secondary Prevention of Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes Mellitus With an Initial HbA1c of >8.5-A Value for Money Analysis
    Azuri, Joseph
    Aboalhasan, Enis
    Sluckis, Ben
    Hammerman, Ariel
    Arbel, Ronen
    CIRCULATION, 2023, 148
  • [46] Effects of once-weekly semaglutide on major adverse cardiovascular events in patients with type 2 diabetes and polyvascular disease: a post hoc analysis of the SUSTAIN 6 trial
    Kobo, O.
    Cavender, M. A.
    Gylvin, S. Hinsch
    Kuhlman, A. B.
    Rasmussen, S.
    Verma, S.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [47] HbA1c, Weight, and Blood Pressure Changes Associated with Early vs. Late Treatment Intensification with Dapagliflozin in UK Primary Care Patients with Type 2 Diabetes
    Wilding, John P.
    Rigney, Una
    Blak, Betina T.
    Nolan, Stephen T.
    Fenici, Peter
    Medina, Jesus
    DIABETES, 2018, 67
  • [48] Sustainability of HbA1c Control of Tirzepatide vs. Insulin Glargine in People with Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
    Pearson, Ewan
    Del Prato, Stefano
    Pavo, Imre
    Franco, Denise R.
    Yang, Zhengyu
    Wiese, Russell
    Kahn, Steven E.
    DIABETES, 2022, 71
  • [49] Tirzepatide Reduces HbA1c and Body Weight Significantly More than Placebo or Semaglutide Irrespective of Baseline Beta-Cell Function-Post Hoc Analysis from SURPASS-1 and SURPASS-2
    Maldonado, Juan M.
    De Block, Christophe
    Frias, Juan P.
    Lee, Clare
    Brown, Katelyn
    Wang, Hui
    Thomas, Melissa K.
    DIABETES, 2023, 72
  • [50] Achievement of International Diabetes Federation targets for HbA1c, blood pressure and cholesterol is glaring low in young people living with type 2 diabetes in India
    Saxena, A.
    Gupta, M.
    Kumar, D.
    Patil, A.
    Singh, N. K.
    Dariya, S. S.
    Meenakshisundaram, L. M.
    Hiremath, V.
    Maheshwari, A.
    Chandra, K. P.
    DIABETIC MEDICINE, 2023, 40
12345